Question · asked by 1 review
Naloxone + oxycodone prolonged release tablets vs oxycodone: Laxation response: patient assessment of change in bowel status at the end of trial
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Naloxone + oxycodone prolonged release tablets vs oxycodone prolonged‐released tablets Laxation response: Patient assessment of change in bowel statuscat the end of trial · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane Headline outcomes only | no estimate extracted | 2 studies · 212 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.